A decade on from the Kigali Amendment, the inhalation industry continues to navigate the transition to low Global Warming Potential (GWP) propellants in pressurised Metered Dose Inhalers (pMDIs). As regulatory requirements evolve and demand for low carbon therapies grows, the hurdles facing developers extend far beyond simple reformulation.
However, the future of inhaled therapy is not limited to low carbon pMDIs alone. The increasing complexity of drug delivery is accelerating demand for broader platform expertise where multifaceted engineering challenges also exist.
In our latest article in Drug Development & Delivery, we explore how Bespak is supporting the next era of inhaled and nasal drug delivery, from significant investment in low carbon pMDI manufacturing to the implementation of advanced analytics. By providing formulation development, device design and contract manufacturing services across platforms, Bespak has the knowledge, flexibility and resources to take on projects of any shape or size.
Read the full article here.
